EVH:NYE-Evolent Health Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 10.43

Change

-0.28 (-2.61)%

Market Cap

N/A

Volume

5.30M

Analyst Target

USD 11.67
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-1.48 (-1.99%)

USD 13.01B
DOCS Doximity Inc

-2.63 (-3.51%)

USD 11.03B
WEAV Weave Communications Inc

-2.63 (-15.57%)

USD 1.25B
MPLN MultiPlan Corporation

-0.19 (-0.64%)

USD 0.30B
AMWL American Well Corp

-0.32 (-2.65%)

USD 0.18B
OWLT Owlet Inc

+0.26 (+5.24%)

USD 0.08B
TDOC Teladoc Inc

-1.18 (-9.30%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
PHR Phreesia Inc

-0.24 (-0.84%)

N/A
VEEV Veeva Systems Inc Class A

-2.95 (-1.29%)

N/A

ETFs Containing EVH

ACTV LeaderShares® Activist L.. 0.00 % 0.00 %

-0.42 (-1.28%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.29% 27% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.29% 27% F 12% F
Trailing 12 Months  
Capital Gain -69.39% 10% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.39% 10% F 1% F
Trailing 5 Years  
Capital Gain -11.38% 75% C 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.38% 75% C 20% F
Average Annual (5 Year Horizon)  
Capital Gain 36.36% 100% F 90% A-
Dividend Return 36.36% 100% F 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 76.49% 50% F 11% F
Risk Adjusted Return 47.53% 90% A- 61% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.